GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Metastatic Ovarian Cancer overview

Metastatic ovarian cancer results from the spread of ovarian cancer cells beyond the ovaries, commonly reaching the peritoneum, liver, lungs, and lymph nodes. Symptoms like abdominal pain, weight loss, and digestive changes may manifest. Diagnosis involves imaging, blood tests, and surgical biopsy. Staging determines treatment strategies, typically involving surgery and chemotherapy. Prognosis varies, influenced by factors such as metastatic extent and treatment response. Ongoing management includes regular monitoring and potential participation in clinical trials for innovative therapies. Early detection remains crucial for optimizing outcomes in the challenging context of metastatic ovarian cancer.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.